In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor

Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress

The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens

Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development

London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study

The Co-CEOs of Summit Therapeutics discuss the ivonescimab vs Keytruda data that was presented at the 2024 World Conference on Lung Cancer

Berlin based T-knife Therapeutics is carrying on the tradition of German leadership in TCR based technologies in oncology

Andreas Eckert, founder of Eckert & Ziegler, is an expert in radio isotopes and how they are used in medicine. A subsidiary, Pentixapharm, is about to be spun off into is own public company

Travere's FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label

The CEO of Marseille based ImCheck Therapeutics on targeting butyrophilin to modulate innate and adaptive immunity

Innate Pharma's Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology

Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest

With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases

Paris based Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system

Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers

France's OSE Immunotherapeutics is moving a cancer vaccine into a second P3 trial while working on other oncology and I&I targets

Paris based Nanobiotix has always had a nanophysics approach to medicine - the ways they are applying it could be expanding soon

The Co-Founder and CEO of HAYA Therapeutics describes the "dark genome" approach that led to a deal today with Eli Lilly for obesity and metabolic disease

The CEO of Tarsus shares an update on the launch of XDEMVY, and what the company is doing to reach more patients in the quarters ahead

Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London